1 Min Read
July 11 (Reuters) - Cytovia Inc :
* Cytovia Inc, Immune Pharmaceuticals’ oncology subsidiary, enters into a definitive agreement with Pint Pharma for the licensing and commercialization of Ceplene® in Latin America
* Cytovia Inc - Pint GMBH will separately enter into an investment agreement, which will lead to an investment of $4 million into Cytovia
* Cytovia Inc - "Intend to immediately initiate regulatory registration of Ceplene in Latam markets based on European approval"
* Cytovia - Massimo Radaelli, executive chairman of Pint, will also join board of co upon completion of investment, effective spin off of co from Immune Source text for Eikon: Further company coverage: